Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Henderson Clinical Trials

Neither a doctor nor a teaching hospital

Research payments

$1,503,450

188 payments

Through program year 2025, Henderson Clinical Trials is reported as receiving $1,503,450 in research payments, across 188 payments.

By program year

3 rows
Year Kind Amount Payments
2025 Research $65,748 18
2024 Research $1,097,890 85
2023 Research $339,812 85

Breakdown

Who paid Research payments · program years 2023–2025
  1. Moderna TX, Inc. $696,319 9 payments
  2. AstraZeneca Pharmaceuticals LP $305,490 9 payments
  3. Chiesi USA, Inc. $218,287 75 payments
  4. Roche Molecular Systems, Inc. $153,258 13 payments
  5. Sun Pharmaceutical Industries Inc. $56,890 7 payments
  6. Jazz Pharmaceuticals Inc. $26,092 69 payments
  7. AstraZeneca UK Limited $19,113 2 payments
  8. Taro Pharmaceuticals USA, Inc. $14,000 2 payments
  9. CSL Behring $14,000 2 payments
Studies the money was for Research payments · program years 2023–2025
  1. A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age $678,244 5 payments
  2. A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. $214,754 73 payments
  3. A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma $203,393 5 payments
  4. Rd006493 $153,258 13 payments
  5. A Randomized Double-Blind Parallel Group Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants with Inadequately Controlled Asthma $82,373 3 payments
  6. RXLC 2118 $70,890 9 payments
  7. An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to Xywav $26,092 69 payments
  8. A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (MIRANDA) $19,724 1 payment
  9. BRISOTE A Multicentre Randomised DoubleBlind Parallel Group ActiveControlled Phase 3b Study to Evaluate the Efficacy and Safety of Benralizumab 30 mg SC in Eosinophilic Asthma Patients Uncontrolled on Medium Dose Inhaled Corticosteroid Plus Long acting 2 Agonist $19,113 2 payments
  10. A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. $18,075 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record